Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Study Treatment Extension Study of AMG 706

Trial Profile

An Open Label Study Treatment Extension Study of AMG 706

Phase of Trial: Phase II

Latest Information Update: 02 Oct 2016

At a glance

  • Drugs Motesanib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 12 Jan 2010 Planned end date changed from 1 Feb 2011 to 1 Feb 2013 as reported by ClinicalTrials.gov.
    • 21 Nov 2009 New source identified and integrated (M.D. Anderson Cancer Center, 2005-0761).
    • 21 Jul 2009 Additional trial locations identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top